Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.

What Was Tested

This phase 3 clinical trial looks at Calcium, Dietary.

The aim of the study was to assess the long-term effects of intravenous pamidronate in FD.

Why It Was Studied

Fibrous dysplasia of bone (FD) is a rare disorder characterized by proliferation of fibrous tissue in bone marrow leading to osteolytic lesions.

It causes bone pain and fractures.

Who Took Part

According to the abstract, 20 patients were involved.

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

Severity of bone pain, number of painful skeletal sites per patient, X-rays of all involved areas, serum alkaline phosphatase, fasting urinary hydroxyproline, and urinary type I collagen C-telopeptide were assessed every 6 months.

How the Study Was Run

The researchers set it up as an open-label study.

Being open-label, the Calcium, Dietary study did not mask who received what.

What Was Measured

PubMed files the paper under topics including Biomarkers, Biopsy, Bone Density, Bone Remodeling, Bone and Bones, Calcium, Dietary and Diphosphonates.

What This Means in Plain Language

The paper is an open-label study of Calcium, Dietary in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: all human trials.